Eli Lilly’s Mounjaro and Zepbound generated over $10 billion in Q3 sales, fueling explosive growth in the obesity drug market. The gold rush has sparked a bidding war between Novo Nordisk and Pfizer for experimental drugmaker Metsera.
The Generics Mindset: Patent Destroyers in Action In the pharmaceutical world, the divide between innovative drug discovery and generic manufacturing…
Stock futures showed minimal movement Thursday night following a significant market sell-off driven by regional banking concerns. The volatility index jumped while Treasury yields fell, indicating heightened investor anxiety. Banking stocks tumbled after several institutions disclosed problematic loan portfolios.
U.S. stock futures were hovering near the flatline on Thursday night following a significant market decline during the previous session, according to reports. The downturn was reportedly fueled by growing concerns about regional banks’ loan practices and broader economic uncertainties.
Novo Nordisk is rapidly cutting thousands of jobs in Denmark, with affected employees forming an unofficial “Club 5,000” support network. According to reports, the pharmaceutical giant aims to complete most layoffs by this week’s autumn holiday as it restructures amid fierce obesity drug competition.
Novo Nordisk is accelerating job cuts in its home country of Denmark, with approximately 5,000 positions being eliminated across manufacturing, research, IT, and quality control departments, according to reports from Reuters. The rapid pace of layoffs has led affected employees to form an unofficial support community dubbed “Club 5,000,” where former colleagues share job tips and organize social gatherings.
